All In Biotech

Drug Trial Radar · NCT05733546

A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder

Last checked: Nov 20, 2026Latest source record: Aug 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 102 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

102

Actual

Start

Jan 30, 2023

Primary completion

Sep 2025

Study completion Sep 2025

Sponsor

Lead sponsor
COMPASS PathwaysIndustry
Sponsor type
Industry
First posted
Feb 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Safety, Tolerability, pharmacokinetics and efficacy of a single administration of COMP360 in participants with recurrent Major Depressive Disorder.

Conditions

  • Major Depressive Disorder

Interventions

  • PsilocybinDrug

    COMP360 Psilocybin administered under supportive conditions

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and tolerability of COMP360 PsilocybinTime frame: Up to Week 6

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Kadima Neuropsychiatry Institute

    La Jolla, California

  • Clinical Neuroscience Solutions Inc

    Jacksonville, Florida

  • Sunstone Therapies

    Rockville, Maryland

  • Elixia MA, LLC

    Springfield, Massachusetts

  • Aims Trial

    Plano, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.